BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 8212747)

  • 1. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P; Schmidt G
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current treatment of supraventricular tachycardia: drug therapy].
    Manz M; Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):430-8. PubMed ID: 8212748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
    Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
    Manz M; Lüderitz B
    Eur Heart J; 1993 Sep; 14 Suppl E():91-8. PubMed ID: 8223763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the right drug: a treatment algorithm for regular supraventricular tachycardias.
    Lévy S; Ricard P
    Eur Heart J; 1997 May; 18 Suppl C():C27-32. PubMed ID: 9152672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of diltiazem in supraventricular paroxysmal tachyarrhythmias].
    De Rosa F; Feraco E; Venneri N; Boncompagni F; Curia F; Guzzo D; Plastina F
    G Ital Cardiol; 1986 Sep; 16(9):776-81. PubMed ID: 3803800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exogenous adenosine as an anti-arrhythmia agent].
    Tebbenjohanns J; Pfeiffer D; Schumacher B; Korte T; Jung W; Lüderitz B
    Z Kardiol; 1996; 85 Suppl 6():191-9. PubMed ID: 9064965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
    Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conservative therapy of supraventricular tachycardias].
    Gmeiner R; Sterz H
    Wien Med Wochenschr; 1984 Oct; 134(19-20):443-7. PubMed ID: 6151320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Catheter ablation in supraventricular tachycardia].
    Pitschner HF; Neuzner J
    Z Kardiol; 1996; 85 Suppl 6():45-60. PubMed ID: 9064982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
    Rae AP
    Am J Cardiol; 1998 Oct; 82(8A):59N-65N. PubMed ID: 9809902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia].
    Vester EG
    Herz; 1997 Jun; 22 Suppl 1():40-50. PubMed ID: 9333591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy of cardiac arrhythmias 199].
    Dietz A; Manz M
    Fortschr Med; 1997 Nov; 115(33):32, 34-6, 38. PubMed ID: 9480278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
    Aouate P; Frank R; Fontaine G; Tonet J; Tageddine R; Benassar A; Turlure A; Jacquemin M; Laborde JP
    Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1869-74. PubMed ID: 8729368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.